Its not something new: it was introduced around 1950 and today it can be used up to 1% worldwide
Moreover, a percentage of patients ranging between 7 and 25%, depending on different dosage, experience adverse events upon PDE5i treatment [59, 60], sometimes manifesting as of moderate or severe entity, the most frequent of which comprise flushing, headache, dyspepsia, back pain, myalgia, dizziness, and rhinitis [10], although discontinuation rates owing to adverse events of PDE5i is generally relatively low, and comprised between 3 and 5% of patients [61]
In a small clinical trial of 25 adolescents, Arbaclofen has been found to rescue slow auditory sensory processing in males with idiopathic ASD [127]
Circ Res 92(1):3240 Martins RC et al (2020) Relaxin and the cardiovascular system: from basic science to clinical practice
For a deeper discussion of this next phase, read what happens after GLP-1 weight loss, including long-term maintenance and metabolic follow-up